---
title: "CGON: Cretostimogene delivers leading efficacy and safety in NMIBC, targeting a large market opportunity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291382086.md"
description: "Cretostimogene, an investigational oncolytic immunotherapy for NMIBC, demonstrates best-in-disease durability, high response rates, and a favorable safety profile across multiple clinical trials. Addressing a multi-billion dollar market, the program is advancing through pivotal studies with regulatory milestones anticipated between 2025 and 2027.Original document: CG Oncology, Inc. [CGON] Slides Release — Jul. 1 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-01T07:44:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291382086.md)
  - [en](https://longbridge.com/en/news/291382086.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291382086.md)
generator: "portal-rs"
---

# CGON: Cretostimogene delivers leading efficacy and safety in NMIBC, targeting a large market opportunity

Cretostimogene, an investigational oncolytic immunotherapy for NMIBC, demonstrates best-in-disease durability, high response rates, and a favorable safety profile across multiple clinical trials. Addressing a multi-billion dollar market, the program is advancing through pivotal studies with regulatory milestones anticipated between 2025 and 2027.

Original document: CG Oncology, Inc. \[CGON\] Slides Release — Jul. 1 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CGON.US](https://longbridge.com/en/quote/CGON.US.md)

## Related News & Research

- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)
- [VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook](https://longbridge.com/en/news/298508921.md)
- [GOOG: AI-driven cloud solutions and diversified models fuel rapid growth and deep enterprise adoption](https://longbridge.com/en/news/298354644.md)
- [Tyra Biosciences reports 79% response rate in Phase 2 bladder cancer study of dabogratinib at 60 mg dose](https://longbridge.com/en/news/298445177.md)
- [CLX: Highlights include timing solutions, network resilience, and steady FY27 outlook](https://longbridge.com/en/news/298432050.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**